RAC1 protein could be a new therapeutic target to fight neurodegeneration in Parkinson’s disease Blog Post

A new research study reveals RAC1 protein could be a new therapeutic target to study the molecular mechanisms related to the neurodegenerative processes in Parkinson’s disease. The study, published in the online edition of the journal Molecular Neurobiology, is led by Antonella Consiglio –head of the Laboratory of Stem Cells and Neuroplasticity at the Institute of Biomedicine of the UB (IBUB) in the Barcelona Science Park and researcher at the Faculty of Medicine and Health Sciences of the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL)– and Esther Dalfo, from the Univesitat Autònoma de Barcelona and Universitat de Vic – Universitat Central de Catalunya.

 

Registration open for the 10th edition of the Summer School on Medicines Blog Post

The 10th Summer School on Medicines (SSM10) will be held in Brazil, in Ribeirão Preto (São Paulo), from March 16–23. The Barcelona Science Park collaborates one more year in this initiative –one of the most innovative and results-oriented programs offered internationally in pharmaceutical sector– organised by the Universitat de Barcelona (UB), Biocat, la Université de Montréal (UdeM) i la Universitat Toulouse III – Paul Sabatier.

 

Jaume Amat, CEO of Specipig, new president of CataloniaBio & HealthTech Blog Post

CataloniaBio & HealthTech has chosen its first president and board of directors today, after the merger of the CataloniaBio association of companies and the HealthTech Cluster last December, at an extraordinary members’ assembly. The new entity, located at the Barcelona Science Park, represents more than 170 companies, as well as collaborating stakeholders such as hospitals, research centres and universities that are leaders in R&D in biomedicine.

 

CERETOX to present its R&D&I in toxicology potential at the UB-TECNIO Conference Blog Post

The UB-TECNIO Conference on Food, Health Sciences and Industrial Systems is to be held at the Barcelona Science Park (PCB) on Tuesday 13 February. The event is organised by the Bosch i Gimpera Foundation (FBG) and will present UB Group TECNIO group and candidate technology to companies which have innovation and development requirements for new products and services. CERETOX is integrated by the PCB’s Experimental Toxicology and Ecotoxicology Technology Platform (UTOX) and the Toxicology Unit of the Faculty of Pharmacy of the University of Barcelona and will be one of the research centres to showcase its potential in R&D&I services for companies.

 

QIAGEN enters into agreement to acquire STAT-Dx Blog Post

Qiagen, a Netherlands-based holding company has entered into an agreement to acquire Stat-Dx –a privately-held company with headquarters at the Barcelona Science Park– for $191 million. The catalan biotec, founded in 2010 by Jordi Carrera and Rafael Bru, is focused on the development, manufacturing and commercialization of “Closer to Care” diagnostic solutions.

 

Chemotargets signs a research collaboration agreement with FDA/CDER Blog Post

The Food and Drug Administration’s Center for Drug Evaluation and Research (FDA-CDER) and Chemotargets –a spin off from the IMIM Hospital del Mar Medical Research Institut and located at the Barcelona Science Park– will work together under a 5-year Research Collaboration Agreement (RCA). The collaboration aims to enhance CDER’s safety assessments of human pharmaceuticals, supporting the FDA’s mission of protecting public health.

 

Bioinformatics company Mind the Byte acquires Intelligent Pharma Blog Post

Mind the Byte a pioneer in the development of technologies based on artificial intelligence, cloud and big data for computational drug design, has acquired 100% of Intelligent Pharma, one of the leaders in Spain in chemoinformatics services for the pharmaceutical and biotechnology industry. Both bioinformatics companyies are headquartered in the Barcelona Science Park (Parc Científic de Barcelona, PCB) which will help the integration process under which Mind the Byte expects to reach €2 million in turnover by 2019.

 

Minoryx starts a phase II/III clinical study of MIN-102 for the treatment of adrenomyeloneuropathy Blog Post

Minoryx Therapeutics –a company specialized in the development of new drugs for orphan diseases, located at the Barcelona Science Park and the TecnoCampus Mataró– announces the start of its pivotal phase II/III clinical trial of MIN-102 for the treatment of adrenomyeloneuropathy (AMN), the most frequent phenotype of X-linked adrenoleukodystrophy (X-ALD). The trial enrolls adult male patients affected by AMN, the most frequent phenotype of X-linked adrenoleukodystrophy (X-ALD).